Sangamo Therapeutics, Inc. company information, Employees & Contact Information

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call Yahoo Finance

1.97 mL/min Kidney Function Improvement: Sangamo's One-Time Gene Therapy Could Transform Fabry Disease Care Stock Titan

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results Business Wire

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering Business Wire

Updated Data Suggests Sangamo’s Gene Therapy ST-920 Improves Renal Function in Fabry Disease CGTLive®

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases Biogen

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Business Wire

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System Business Wire

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec Business Wire

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease Business Wire

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile Business Wire

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases Business Wire

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain Business Wire

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate Business Wire

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results Business Wire

Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease Business Wire

Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell Therapy Programs CGTLive®

One Big Step Away From BLA Submission for Sangamo’s Fabry Gene Therapy CGTLive®

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) Seeking Alpha

Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) Seeking Alpha

Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies PR Newswire

Earnings call transcript: Sangamo Therapeutics Q2 2025 earnings miss, stock drops Investing.com

Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction (NASDAQ:SGMO) Seeking Alpha

Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call Investing.com

Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors PR Newswire

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing The AI Journal

Sangamo Therapeutics to Acquire TxCell PR Newswire

Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data Fierce Biotech

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec… Trifecta Soon? (NASDAQ:SGMO) Seeking Alpha

BIOGEN IDEC AND SANGAMO BIOSCIENCES ANNOUNCE GLOBAL COLLABORATION TO DEVELOP TREATMENTS FOR HEMOGLOBINOPATHIES Biogen

Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology CGTLive®

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2025 Earnings Call Transcript Insider Monkey

Jason Fontenot, PhD, on Addressing Unmet Needs in Neuropathic Pain and Prion Disease With Zinc Finger Genome Regulation CGTLive®

SGMO Stock Price and Chart — NASDAQ:SGMO TradingView

The State of Gene and Cell Therapy for Sickle Cell Disease HCPLive

Sangamo BioSciences to Acquire Ceregene PR Newswire

Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia PR Newswire

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking (NASDAQ:SGMO) Seeking Alpha

In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline? Frontiers

Biogen, Novartis deliver one-two punch to Sangamo, walking away from deals in quick succession Fierce Biotech

Persistent repression of tau in the brain using engineered zinc finger protein transcription factors Science | AAAS

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 The Manila Times

Sangamo Club to close doors Friday after 133 years The State Journal-Register

Sangamo Announces FDA Clearance Of Investigational New Drug Application Bioprocess Online

No Time to Pause: Companies Abandon Lagging Cell Therapy Programs CGTLive®

Leading Top 10 Companies in Genome Editing P&S Intelligence

Dr Alan P Wolffe 1959–2001 Nature

Zinc-finger protein-targeted gene regulation: Genomewide single-gene specificity PNAS